Lidocaine Hydrochloride And Hydrocortisone Acetate Gel
NDC Package 13925-164-20
Package Information
Lidocaine Hydrochloride And Hydrocortisone Acetate gel is product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. This formulation utilizes a gel delivery system. Marketed by Seton Pharmaceuticals, this product is identified by NDC 13925-164.
Identification & Billing
- RxCUI: 1012223 - lidocaine HCl 3 % / hydrocortisone acetate 2.5 % Rectal Gel
- RxCUI: 1012223 - hydrocortisone acetate 0.025 MG/MG / lidocaine hydrochloride 0.03 MG/MG Rectal Gel
- RxCUI: 1012223 - hydrocortisone acetate 2.5 % / lidocaine HCl 3 % Rectal Gel
Clinical Specifications
- Amide Local Anesthetic - [EPC] (Established Pharmacologic Class)
- Amides - [CS]
- Antiarrhythmic - [EPC] (Established Pharmacologic Class)
- Corticosteroid Hormone Receptor Agonists - [MoA] (Mechanism of Action)
- Corticosteroid - [EPC] (Established Pharmacologic Class)
- Local Anesthesia - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 13925 - Seton Pharmaceuticals
- 13925-164 - Lidocaine Hydrochloride And Hydrocortisone Acetate
- 13925-164-20 - 20 TUBE in 1 KIT / 7 g in 1 TUBE (13925-164-07)
- 13925-164 - Lidocaine Hydrochloride And Hydrocortisone Acetate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 13925-164-20 identifies a specific commercial package of 20 tube in 1 kit / 7 g in 1 tube (13925-164-07) of Lidocaine Hydrochloride And Hydrocortisone Acetate, a human prescription drug labeled by Seton Pharmaceuticals. This gel is formulated for rectal use and contains hydrocortisone acetate; lidocaine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Seton Pharmaceuticals on June 17, 2011. The current certification is valid through December 31, 2026.
How is this Seton Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 13925016420. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.